Clinical trials: Malaria
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is non-inferior to mefloquine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum.
- Trial name
- NCT00082576
- Testing
- Azithromycin/Chloroquine, Mefloquine
- Where
- 6 sites in Ghana, Mali and 2 more
- Volunteers
- 238 people
- Sponsor
- Pfizer
Malaria
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This was a randomized, dose-escalation Phase I/IIa study to evaluate safety, tolerability, immunogenicity and efficacy of an investigational RNA-based vaccine (BNT165e) for prevention of P.
- Trial name
- NCT06069544
- Testing
- BNT165c, BNT165d
- Where
- 5 sites in United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria
- Trial name
- PLATINUM (NCT05750628)
- Testing
- INE963, KAE609 (Cipargamin), SoC (Coartem)
- Where
- 12 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 327 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria
This study is being conducted to further evaluate the safety and clinical outcomes of Coartem® Baby (artemether/lumefantrine 5 mg/60 mg) in neonates and infants weighing ≥2 kg to <5 kg with uncomplicated malaria due to Plasmodium…
- Trial name
- NCT07713602
- Testing
- Coartem® Baby
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Falciparum Malaria
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China).
- Trial name
- NCT00894374
- Testing
- Artesunate (Test), Artesunate (Comparator)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cure Rate
A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day
- Trial name
- NCT01860989
- Testing
- KAE609
- Where
- 4 sites in Thailand, Vietnam
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Malaria
Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults
The study is designed to establish the best dose to safely infect healthy individuals with Plasmodium falciparum sporozoites (PfSPZ) by injection.
- Trial name
- NCT01771848
- Testing
- PfSPZ Challenge
- Where
- 2 sites in Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Asymptomatic Parasitemia In Pregnancy
Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa
The study will be conducted in asymptomatic pregnant women with P. falciparum parasitemia. The subjects will be given 3 day dosing regiment of the fixed-dose combination of Azithromycin and Chloroquine.
- Trial name
- NCT01103713
- Testing
- Azithromycin plus chloroquine
- Where
- 7 sites in Benin, Kenya and 3 more
- Volunteers
- 168 people
- Sponsor
- Pfizer